Drug Trial Radar · NCT06806137
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
May 15, 2025
Primary completion
Dec 14, 2026
Study completion May 3, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 15 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to healthy children. 3 months after first dose at 12 to 15 months. The study will be conducted in children who have not previously contracted varicella or received a varicella vaccination.
Conditions
- Chickenpox
Interventions
Investigational varicella vaccineBiological
Investigational varicella vaccine administered subcutaneously.
Marketed varicella vaccineBiological
Marketed varicella vaccine administered subcutaneously.
MMR vaccineBiological
MMR vaccine co-administered subcutaneously or intramuscularly.
Hepatitis A vaccineBiological
Hepatitis A vaccine co-administered intramuscularly.
PCV (pneumococcal conjugate vaccine) 13Biological
The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
PCV 20Biological
The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
VaxneuvanceBiological
The Vaxneuvance (15-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with seroresponse to Varicella Zoster Virus (VZV) anti- glycoprotein E (gE) IgG for 2 doses of VNS vaccine compared to 2 doses of VVTime frame: At Day 133 (43 days post-dose 2)
- Geometric Mean Concentration (GMC) of anti-VZV gE IgG for 2 doses of VNS vaccine compared to 2 doses of VVTime frame: At Day 133 (within 43 days post-dose 2)
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Constanza, Dominican Republic · Recruiting
GSK Investigational Site
Santo Domingo Oeste, Dominican Republic · Recruiting
GSK Investigational Site
Salvaleón de Higüey, La Altagracia Province, Dominican Republic · Recruiting
GSK Investigational Site
San Pedro Sula, Honduras · Recruiting
GSK Investigational Site
Tegucigalpa, Honduras · Recruiting
GSK Investigational Site
Tegucigalpa, Honduras · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.